Hepion pharmaceuticals schedules conference call to review topline results from phase 2 ‘altitude-nash' liver function trial of rencofilstat

Edison, n.j., may 19, 2023 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“nash”), hepatocellular carcinoma (“hcc”), and other chronic diseases, today announced that it expects to release topline results from the phase 2 altitude-nash clinical trial before the market opens on monday, may 22, 2023.
HEPA Ratings Summary
HEPA Quant Ranking